Wuhan YZY Biopharma Co. Ltd. is a biotech company focused on innovative medicines based on breakthroughs in molecular biology. Founded in 2010 and headquartered at Wuhan Biolake in China, the company aims to target previously "undruggable" disease targets with bi-specific antibodies, MicroRNAs, and RNAi for creating transformative new drug discovery. With a 4,000 square meter R&D center and plans for a 25,000-square-meter manufacturing base, YZY is well-equipped for mass producing therapeutic antibody products. The company's research pipeline includes tumor therapeutic antibodies and cancer stem cells (CSCs).
YZY's strategy involves translating cancer biology into robust drug discovery capabilities while building a significant product pipeline for commercialization alone or with partners. With the aim of providing physicians with novel antibodies and minimizing toxic side effects, the company is making significant investments in its technology platforms including a Flow Cytometry Core Facility, Microarrays, Pre-clinical Drug Screening, and Bio-therapy of Tumor.
The recent CNY200.00M Series C investment in July 2022 showcases investor confidence in the company's vision and capabilities. With a strong scientific team and a focus on personalized medicine, YZY is poised to have a significant impact in the field of biopharmaceuticals and cancer therapy.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series C | CNY200.00M | - | 04 Jul 2022 | |
| Series B | CNY250.00M | 4 |
|
13 Sep 2021 |
No recent news or press coverage available for Wuhan YZY Biopharma Co. Ltd..
We care about your data, and we'd love to use cookies make your experience better.
